S1 Biopharma's non-hormonal therapies work uniquely by restoring the natural balance of neurotransmitters in the brain.

The company’s lead product candidate, Lorexys, is currently positioned to advance to a Phase IIb clinical trial for the treatment of hypoactive sexual desire disorder in women.